Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
ARCHIVE NBI Moves Its Tokyo Office to Osaki
September 24, 2007
-
ARCHIVE Development of New PPAR Agonists Extremely Difficult: Dr Obayashi
September 24, 2007
-
ARCHIVE Innovex, So-net M3 to Provide MR Activities Assessing Service
September 24, 2007
-
ARCHIVE Need to Legalize GL on Clinical Research Stressed by Committee Members
September 24, 2007
-
ARCHIVE Kyowa Hakko Recalls Coniel Tab due to Contamination Problem
September 24, 2007
-
ARCHIVE R&D NEWS IN BRIEF
September 24, 2007
-
ARCHIVE BUSINESS NEWS IN BRIEF
September 24, 2007
-
ARCHIVE OPINION/Secrets behind a Winning Recruitment Team
September 24, 2007
-
ARCHIVE TOPICS/Banyu Most Often Comes to Mind for its Female MRs: Nextit Survey
September 24, 2007
-
ARCHIVE FY2007 Annual Report on Health and Welfare Published
September 24, 2007
-
ARCHIVE Korosho to Enhance Quality Surveillance System for Generics
September 24, 2007
-
ARCHIVE 24.7 Million Units of Influenza Vaccines to Be Supplied for Next Season
September 24, 2007
-
ARCHIVE GENERICS NEWS IN BRIEF
September 24, 2007
-
ARCHIVE European GL on Hypertension, Coronary Artery Disease Revised
September 24, 2007
-
ARCHIVE Mr Abe's Decision to Resign Sends Out Shockwave
September 24, 2007
-
ARCHIVE Disinfection in Boiling SDS Should Be Made Obligatory to Prevent Secondary Infection of CJD
September 24, 2007
-
ARCHIVE Korosho to Encourage Innovation While Optimizing Healthcare Expenditures: Mr Erikawa
September 24, 2007
-
ARCHIVE MEDICAL DEVICE NEWS IN BRIEF
September 24, 2007
-
ARCHIVE Benefits of Research Must Be Returned to the People: Mr Toguchi
September 24, 2007
-
ARCHIVE New Sales Strategy Going Extremely Well: Mr Kashiwagi of sanofi-aventis
September 24, 2007
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…